|Slideshows|October 23, 2019

When Eating Disorders and Psychosis Co-Exist: 6 Take Home Points

The body image disturbance at the heart of anorexia nervosa is a false perception akin to the perceptual disorders found in schizophrenia.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Improving Outcomes in Schizophrenia With Long-Acting Injectables: Insights from the Southern Florida Psychiatry Conference

ByJessica Walters

November 21st 2025

Benefits of Long-Acting Injectable Antipsychotics: An Overview From Southern Florida Psychiatry Conference

ByLeah Kuntz

November 21st 2025

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

ByBrian Miller, MD, PhD, MPH

November 17th 2025

schizophrenia cobenfy data analysis inpatient

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

ByJessica Walters

November 14th 2025

iclepertin cognitive impairment schizophrenia

Iclepertin Found Ineffective in Treating Cognitive Impairment Associated With Schizophrenia

ByJessica Walters

November 13th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

When Eating Disorders and Psychosis Co-Exist: 6 Take Home Points

Newsletter

Related Content

Improving Outcomes in Schizophrenia With Long-Acting Injectables: Insights from the Southern Florida Psychiatry Conference

Benefits of Long-Acting Injectable Antipsychotics: An Overview From Southern Florida Psychiatry Conference

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

Iclepertin Found Ineffective in Treating Cognitive Impairment Associated With Schizophrenia

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

The Epstein Files, the Abuse of Women, and Psychiatry

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking